Literature DB >> 14531176

[Consensus recommendations on drug treatment of bronchial asthma in children and adolescents. 1. Addendum (2003). Austrian Society for Pediatrics and Adolescent Medicine and Austrian Society for Lung Diseases and Tuberculosis].

Ernst Eber1, Thomas Frischer, Manfred Götz, Elisabeth Horak, Herbert Kurz, Josef Riedler, Rudolf Schmitzberger, Maximilian Zach.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14531176     DOI： 10.1007/bf03040457

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   1.704


× No keyword cloud information.
  9 in total

1.  [Consensus guidelines for drug therapy of bronchial asthma in children and adolescents. Austrian Society of Pediatrics and Adolescent Medicine and Austrian Society for Lung Diseases and Tuberculosis].

Authors:  T Frischer; E Eber; I Eichler; E Horak; J Riedler; M Götz; M Zach
Journal:  Wien Klin Wochenschr       Date:  1999-11-12       Impact factor: 1.704

2.  British guideline on the management of asthma.

Authors: 
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

3.  Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma.

Authors:  W Busse; H Nelson; J Wolfe; C Kalberg; S W Yancey; K A Rickard
Journal:  J Allergy Clin Immunol       Date:  1999-06       Impact factor: 10.793

4.  Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids.

Authors:  A M Wilson; O J Dempsey; E J Sims; B J Lipworth
Journal:  Chest       Date:  2001-04       Impact factor: 9.410

5.  Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy.

Authors:  J E Fish; E Israel; J J Murray; A Emmett; R Boone; S W Yancey; K A Rickard
Journal:  Chest       Date:  2001-08       Impact factor: 9.410

6.  Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast.

Authors:  H S Nelson; W W Busse; E Kerwin; N Church; A Emmett; K Rickard; K Knobil
Journal:  J Allergy Clin Immunol       Date:  2000-12       Impact factor: 10.793

7.  Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids.

Authors:  H S Nelson; R A Nathan; C Kalberg; S W Yancey; K A Rickard
Journal:  MedGenMed       Date:  2001-07-05

8.  Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype.

Authors:  B J Lipworth; O J Dempsey; I Aziz; A M Wilson
Journal:  Am J Med       Date:  2000-08-01       Impact factor: 4.965

9.  Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma.

Authors:  A S Yurdakul; H C Calişir; B Tunçtan; M Ogretensoy
Journal:  Respir Med       Date:  2002-05       Impact factor: 3.415
  9 in total
  4 in total

1.  [Guideline for the treatment of bronchial asthma in children and adolescents].

Authors:  Josef Riedler; Ernst Eber; Thomas Frischer; Manfred Götz; Elisabeth Horak; Maximilian Zach
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

2.  [Recurring obstructive bronchitis and asthmatic bronchitis in preschool aged children].

Authors:  Manfred Götz; Ernst Eber; Thomas Frischer; Elisabeth Horak; Herbert Kurz; Josef Riedler; Rudolf Schmitzberger; Maximilian Zach
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

3.  [Long-acting beta-2 agonists in pediatric asthma therapy--friend or foe].

Authors:  Herbert Kurz; Ernst Eber; Thomas Frischer; Manfred Götz; Elisabeth Horak; Josef Riedler; Rudolf Schmitzberger; Maximilian Zach
Journal:  Wien Klin Wochenschr       Date:  2006-06       Impact factor: 1.704

Review 4.  [Wheezing in infants and toddlers: new insights].

Authors:  Elisabeth Horak
Journal:  Wien Klin Wochenschr       Date:  2004-01-31       Impact factor: 2.275
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.